Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1791323 | 0.90 | EPHX2 (0.35) | MCHR1 | |
| SCHEMBL1790081 | 0.89 | CYP11B2 (0.34) | PRMT5WDR77DPP4DPP7HRH3 | |
| SCHEMBL1786839 | 0.89 | CYP11B2 (0.34) | PRMT5WDR77DPP4DPP7HRH3 | |
| SCHEMBL1789058 | 0.86 | DPP4 (0.39) | F10MCHR1PRMT5WDR77RORC | |
| SCHEMBL1788768 | 0.84 | F10 (0.39) | F10MCHR1PRMT5WDR77RORC | |
| SCHEMBL1788530 | 0.82 | HRH3 (0.43) | F10HRH3 | |
| SCHEMBL1791090 | 0.82 | WDR5 (0.34) | RORC | |
| SCHEMBL1978541 | 0.82 | KDM2B (0.34) | PRMT5WDR77DPP4DPP7 | |
| SCHEMBL1791326 | 0.78 | F10 (0.38) | F10MCHR1PRMT5WDR77RORC | |
| SCHEMBL1791202 | 0.77 | EPHX2 (0.37) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | F10 2095/4885MCHR1 191/4885PRMT5 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.